163 related articles for article (PubMed ID: 38316746)
1. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract][Full Text] [Related]
3. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
4. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
[No Abstract] [Full Text] [Related]
5. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
[No Abstract] [Full Text] [Related]
6. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
7. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
[TBL] [Abstract][Full Text] [Related]
8. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
Preudhomme C; Renneville A; Bourdon V; Philippe N; Roche-Lestienne C; Boissel N; Dhedin N; André JM; Cornillet-Lefebvre P; Baruchel A; Mozziconacci MJ; Sobol H
Blood; 2009 May; 113(22):5583-7. PubMed ID: 19357396
[TBL] [Abstract][Full Text] [Related]
9. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression.
Bluteau D; Glembotsky AC; Raimbault A; Balayn N; Gilles L; Rameau P; Nurden P; Alessi MC; Debili N; Vainchenker W; Heller PG; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2708-18. PubMed ID: 22898599
[TBL] [Abstract][Full Text] [Related]
10. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).
Shiba N; Hasegawa D; Park MJ; Murata C; Sato-Otsubo A; Ogawa C; Manabe A; Arakawa H; Ogawa S; Hayashi Y
Blood; 2012 Mar; 119(11):2612-4. PubMed ID: 22138511
[TBL] [Abstract][Full Text] [Related]
11. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
[TBL] [Abstract][Full Text] [Related]
12. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
Iizuka H; Kagoya Y; Kataoka K; Yoshimi A; Miyauchi M; Taoka K; Kumano K; Yamamoto T; Hotta A; Arai S; Kurokawa M
Exp Hematol; 2015 Oct; 43(10):849-57. PubMed ID: 26021490
[TBL] [Abstract][Full Text] [Related]
13. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.
Owen CJ; Toze CL; Koochin A; Forrest DL; Smith CA; Stevens JM; Jackson SC; Poon MC; Sinclair GD; Leber B; Johnson PR; Macheta A; Yin JA; Barnett MJ; Lister TA; Fitzgibbon J
Blood; 2008 Dec; 112(12):4639-45. PubMed ID: 18723428
[TBL] [Abstract][Full Text] [Related]
14. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.
Heller PG; Glembotsky AC; Gandhi MJ; Cummings CL; Pirola CJ; Marta RF; Kornblihtt LI; Drachman JG; Molinas FC
Blood; 2005 Jun; 105(12):4664-70. PubMed ID: 15741216
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.
Glembotsky AC; Bluteau D; Espasandin YR; Goette NP; Marta RF; Marin Oyarzun CP; Korin L; Lev PR; Laguens RP; Molinas FC; Raslova H; Heller PG
J Thromb Haemost; 2014 May; 12(5):761-72. PubMed ID: 24606315
[TBL] [Abstract][Full Text] [Related]
16. [Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].
Osato M; Nambu A
Rinsho Ketsueki; 2020; 61(6):687-696. PubMed ID: 32624544
[TBL] [Abstract][Full Text] [Related]
17. Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
Yoshimi A; Toya T; Kawazu M; Ueno T; Tsukamoto A; Iizuka H; Nakagawa M; Nannya Y; Arai S; Harada H; Usuki K; Hayashi Y; Ito E; Kirito K; Nakajima H; Ichikawa M; Mano H; Kurokawa M
Nat Commun; 2014 Aug; 5():4770. PubMed ID: 25159113
[TBL] [Abstract][Full Text] [Related]
18. Myeloid neoplasms with germ line RUNX1 mutation.
Hayashi Y; Harada Y; Huang G; Harada H
Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
[TBL] [Abstract][Full Text] [Related]
19. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
20. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
